Vaxart (MEX:VXRT) Other Current Receivables: MXN909 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

MEX:VXRT Vaxart Inc MEX:VXRT
50 GF Score
Price MXN12.00
! 3 Warning Signs
View Full Analysis

What is Vaxart Other Current Receivables?

Vaxart MEX:VXRT 50 Other Current Receivables is MXN909 Mil as of Mar. 2026. GuruFocus rates MEX:VXRT with a GF Score™ of 50/100. The stock has 3 warning signs investors should review.

Vaxart's Other Current Receivables for the quarter that ended in Mar. 2026 was MXN909 Mil.

Vaxart's quarterly Other Current Receivables declined from Sep. 2025 (MXN793.00 Mil) to Dec. 2025 (MXN662.27 Mil) but then increased from Dec. 2025 (MXN662.27 Mil) to Mar. 2026 (MXN909.48 Mil).

Vaxart's annual Other Current Receivables increased from Dec. 2023 (MXN0.00 Mil) to Dec. 2024 (MXN129.47 Mil) and increased from Dec. 2024 (MXN129.47 Mil) to Dec. 2025 (MXN662.27 Mil).

Vaxart Other Current Receivables Related Terms

Vaxart Other Current Receivables Historical Data

* Premium members only.

The historical data trend for Vaxart's Other Current Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Vaxart Other Current Receivables Chart

Vaxart Annual Data
Trend Jun16 Jun17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Current Receivables
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 129.47 662.27

Vaxart Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Other Current Receivables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 299.14 692.56 793.00 662.27 909.48
MEX:VXRT
50GF Score
Vaxart Inc MEX:VXRT
Other Current Receivables is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Vaxart Other Current Receivables Calculation

GuruFocus uses a standardized financial statement format for all companies. GuruFocus lists Accounts Receivable, Notes Receivable , Loans Receivable and Other Current Receivables under the "Total Receivables" section.

What does a Other Current Receivables of MXN909 Mil mean?
Vaxart (MEX:VXRT) has a Other Current Receivables of MXN909 Mil as of Mar. 2026. Other Current Receivables is other current receivables of that not otherwise classified. View historical data on Vaxart and its competitors.
Is Vaxart's Other Current Receivables too high?
Vaxart's current Other Current Receivables is MXN909 Mil. Overall, Vaxart has a GF Score™ of 50/100, reflecting its overall financial health beyond just this single metric.
How does Vaxart's Other Current Receivables compare to VTVT and SPRB?
Vaxart's Other Current Receivables of MXN909 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Current Receivables for a Biotechnology company?
A good Other Current Receivables depends on the Biotechnology industry context. However, Other Current Receivables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Current Receivables mean?
A high Other Current Receivables can signal that a stock is expensive relative to its fundamentals. Other Current Receivables is other current receivables of that not otherwise classified. View historical data on Vaxart and its competitors. Vaxart's current Other Current Receivables is MXN909 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vaxart stock overvalued right now?
Vaxart (MEX:VXRT) has a current Other Current Receivables of MXN909 Mil. The current Other Current Receivables is MXN909 Mil. Vaxart's overall GF Score™ is 50/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Current Receivables calculated?
Other Current Receivables is calculated from a company's financial statements. For Vaxart (MEX:VXRT), the current Other Current Receivables is MXN909 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Vaxart Business Description

Other Exchanges VXRT:USA
Address 170 Harbor Way, Suite 300, South San Francisco, CA, USA, 94080
Vaxart Inc is a clinical-stage biotechnology company. It focuses on the development of oral recombinant vaccines based on its Vector Adjuvant Antigen Standardized Technology to protect against a wide range of infectious diseases. The products under its tablet pipeline consist of the treatment of Coronavirus, Norovirus, Seasonal Influenza, RSV(respiratory syncytial virus), and HPV(Human papillomavirus) Therapeutic. It operates in a single segment, which is the discovery and development of oral recombinant protein vaccines. Geographically, all the business activity functions through the region of the United States.
50GF Score

Get the complete analysis for MEX:VXRT

Other Current Receivables is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN12.00
Price